title: Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetes.
abstract: A bidirectional relationship seems to exist between diabetes mellitus and development of pancreatic tumors. Metformin, the most widely used drug in the treatment of Type 2 diabetes mellitus, has recently emerged as a potentially active agent in cancer chemoprevention and treatment. In this article, we discuss the potential correlation between glycemic status, administration of antiglycemic treatments, such as metformin or insulin, and prognosis of pancreatic neuroendocrine tumors patients treated with everolimus and octreotide, on the basis of existing evidence and our experience.
authors.affiliation: Medical Oncology Unit 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
authors.forename: Sara
authors.initials: S
authors.lastname: Pusceddu
authors.affiliation: Day Hospital/Outpatient Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
authors.forename: Roberto
authors.initials: R
authors.lastname: Buzzoni
authors.affiliation: Medical Oncology Unit 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.|IFOM, FIRC Institute of Molecular Oncology, 20139 Milan, Italy.
authors.forename: Claudio
authors.initials: C
authors.lastname: Vernieri
authors.affiliation: Day Hospital/Outpatient Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
authors.forename: Laura
authors.initials: L
authors.lastname: Concas
authors.affiliation: Department of Information & Bioengineering, Politecnico University, Milan, Italy.
authors.forename: Sara
authors.initials: S
authors.lastname: Marceglia
authors.affiliation: Department of Surgical Sciences & Integrated Diagnostics, School of Medicine, Genova University, Genoa, Italy.
authors.forename: Luca
authors.initials: L
authors.lastname: Giacomelli
authors.affiliation: Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
authors.forename: Massimo
authors.initials: M
authors.lastname: Milione
authors.affiliation: Day Hospital/Outpatient Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
authors.forename: Livia
authors.initials: L
authors.lastname: Leuzzi
authors.affiliation: Day Hospital/Outpatient Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
authors.forename: Daniela
authors.initials: D
authors.lastname: Femia
authors.affiliation: Medical Oncology Unit 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
authors.forename: Barbara
authors.initials: B
authors.lastname: Formisano
authors.affiliation: Gastro-Intestinal Surgery, Liver Transplantation & Hepatology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Mazzaferro
authors.affiliation: Medical Oncology Unit 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
authors.forename: Filippo
authors.initials: F
authors.lastname: de Braud
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D015897:Comorbidity; D003920:Diabetes Mellitus / Q000188:drug therapy* / Q000453:epidemiology; D000068338:Everolimus / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008687:Metformin / Q000627:therapeutic use; D018358:Neuroendocrine Tumors / Q000188:drug therapy* / Q000453:epidemiology; D015282:Octreotide / Q000627:therapeutic use; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000453:epidemiology
chemical_list: D000970:Antineoplastic Agents; D007004:Hypoglycemic Agents; D008687:Metformin; D000068338:Everolimus; D015282:Octreotide
keywords: diabetes; mTOR inhibitor; metformin; pancreatic neuroendocrine tumors